Repeated Administration of the Cannabinoid WIN Alters the Isoflurane-Sparing Effect of Morphine and Dexmedetomidine

Overview

Journal Vet Sci

Publisher MDPI

Specialty Veterinary Medicine

Date 2023 May 26

PMID 37235393

Authors

Jose Antonio Ibancovichi

Julio Raul Chavez-Monteagudo

Pedro Sanchez-Aparicio

Marco Antonio De Paz-Campos

Affiliations

Soon will be listed here.

Abstract

Methods: Prior to the administration of morphine, the MAC was measured in both untreated rats (MAC ) and those treated with a cannabinoid (MAC ). The effects of morphine (MAC ) and dexmedetomidine (MAC ) on untreated rats and rats treated for 21 days with the cannabinoids (MAC ) and (MAC ) were also studied.

Results: MAC was 1.32 ± 0.06, and MAC was 1.69 ± 0.09. MAC was 0.97 ± 0.02 (26% less than MAC ). MAC was 1.55 ± 0.08 (8% less than MAC ), MAC was 0.68 ± 0.10 (48% less than MAC ), and MAC was 0.67 ± 0.08 (60% less than MAC ).

Conclusions: Medication with a cannabinoid for 21 days augmented the MAC of isoflurane. The sparing effect of morphine on isoflurane is lower in rats constantly medicated with a cannabinoid. The sparing effect of dexmedetomidine on the minimum alveolar concentration of isoflurane is greater in rats repeatedly medicated with a cannabinoid.

References

Chavez-Monteagudo J, Ibancovichi J, Sanchez-Aparicio P, Recillas-Morales S, Osorio-Avalos J, De Paz-Campos M . Minimum Alveolar Concentration of Isoflurane in Rats Chronically Treated with the Synthetic Cannabinoid WIN 55,212-2. Animals (Basel). 2022; 12(7). PMC: 8997027. DOI: 10.3390/ani12070853. View

de Segura I, Criado A, Santos M, Tendillo F . Aspirin synergistically potentiates isoflurane minimum alveolar concentration reduction produced by morphine in the rat. Anesthesiology. 1998; 89(6):1489-94. DOI: 10.1097/00000542-199812000-00027. View

Wang K, Wu M, Xu J, Wu C, Zhang B, Wang G . Effects of dexmedetomidine on perioperative stress, inflammation, and immune function: systematic review and meta-analysis. Br J Anaesth. 2019; 123(6):777-794. DOI: 10.1016/j.bja.2019.07.027. View

Eger 2nd E, Xing Y, Laster M, Sonner J . Alpha-2 adrenoreceptors probably do not mediate the immobility produced by inhaled anesthetics. Anesth Analg. 2003; 96(6):1661-1664. DOI: 10.1213/01.ANE.0000061584.25288.98. View

Page M, Oropeza V, Sparks S, Qian Y, Menko A, Van Bockstaele E . Repeated cannabinoid administration increases indices of noradrenergic activity in rats. Pharmacol Biochem Behav. 2007; 86(1):162-8. PMC: 1941574. DOI: 10.1016/j.pbb.2006.12.020. View

Davy A, Fessler J, Fischler M, Le Guen M . Dexmedetomidine and general anesthesia: a narrative literature review of its major indications for use in adults undergoing non-cardiac surgery. Minerva Anestesiol. 2017; 83(12):1294-1308. DOI: 10.23736/S0375-9393.17.12040-7. View

Pan S, Liu G, Lin J, Jin Y . Efficacy and Safety of Dexmedetomidine Premedication in Balanced Anesthesia: A Systematic Review and Meta-Analysis in Dogs. Animals (Basel). 2021; 11(11). PMC: 8614454. DOI: 10.3390/ani11113254. View

Ide S, Satoyoshi H, Minami M, Satoh M . Amelioration of the reduced antinociceptive effect of morphine in the unpredictable chronic mild stress model mice by noradrenalin but not serotonin reuptake inhibitors. Mol Pain. 2015; 11:47. PMC: 4531527. DOI: 10.1186/s12990-015-0051-0. View

Corchero J, Manzanares J, Fuentes J . Cannabinoid/opioid crosstalk in the central nervous system. Crit Rev Neurobiol. 2004; 16(1-2):159-72. DOI: 10.1615/critrevneurobiol.v16.i12.170. View

10.

Whiting P, Wolff R, Deshpande S, Di Nisio M, Duffy S, Hernandez A . Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015; 313(24):2456-73. DOI: 10.1001/jama.2015.6358. View

11.

Abrams D, Couey P, Shade S, Kelly M, Benowitz N . Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther. 2011; 90(6):844-51. DOI: 10.1038/clpt.2011.188. View

12.

Boehnke K, Litinas E, Clauw D . Medical Cannabis Use Is Associated With Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients With Chronic Pain. J Pain. 2016; 17(6):739-44. DOI: 10.1016/j.jpain.2016.03.002. View

13.

Tanda G, Pontieri F, Di Chiara G . Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science. 1997; 276(5321):2048-50. DOI: 10.1126/science.276.5321.2048. View

14.

Jugl S, Okpeku A, Costales B, Morris E, Alipour-Haris G, Hincapie-Castillo J . A Mapping Literature Review of Medical Cannabis Clinical Outcomes and Quality of Evidence in Approved Conditions in the USA from 2016 to 2019. Med Cannabis Cannabinoids. 2021; 4(1):21-42. PMC: 8525213. DOI: 10.1159/000515069. View

15.

Quasha A, Eger 2nd E, Tinker J . Determination and applications of MAC. Anesthesiology. 1980; 53(4):315-34. DOI: 10.1097/00000542-198010000-00008. View

16.

Bloom A, Dewey W . A comparison of some pharmacological actions of morphine and delta9-tetrahydrocannabinol in the mouse. Psychopharmacology (Berl). 1978; 57(3):243-8. DOI: 10.1007/BF00426745. View

17.

Charan J, Biswas T . How to calculate sample size for different study designs in medical research?. Indian J Psychol Med. 2013; 35(2):121-6. PMC: 3775042. DOI: 10.4103/0253-7176.116232. View

18.

Kumar P, Mahato D, Kamle M, Borah R, Sharma B, Pandhi S . Pharmacological properties, therapeutic potential, and legal status of Cannabis sativa L.: An overview. Phytother Res. 2021; 35(11):6010-6029. DOI: 10.1002/ptr.7213. View

19.

Antognini J, Schwartz K . Exaggerated anesthetic requirements in the preferentially anesthetized brain. Anesthesiology. 1993; 79(6):1244-9. DOI: 10.1097/00000542-199312000-00015. View

20.

Hine B . Morphine and delta 9-tetrahydrocannabinol: two-way cross tolerance for antinociceptive and heart-rate responses in the rat. Psychopharmacology (Berl). 1985; 87(1):34-8. DOI: 10.1007/BF00431774. View